Abeona Therapeutics (ABEO) director sells 18,160 shares to cover tax

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

ABEONA THERAPEUTICS INC. director Christine Berni Silverstein reported an open-market sale of 18,160 shares of common stock. The shares were sold at a weighted average price of $5.7101 per share. According to the footnotes, this sale was made to cover tax obligations arising from the vesting of restricted stock awards. After the transaction, she directly owned 119,562 shares of Abeona common stock.

Insights

Director sold shares mainly to cover taxes on vested stock awards.

Director Christine Berni Silverstein sold 18,160 shares of Abeona Therapeutics common stock at a weighted average price of $5.7101. A footnote states the sale’s purpose was to cover tax obligations from vesting restricted stock awards, making this a mechanistic, compensation-related transaction.

Following the sale, she held 119,562 shares directly, indicating she retains a substantial equity position. Because the sale is tied to tax withholding rather than discretionary portfolio changes, its informational value for outside investors is limited, and it does not materially alter the broader investment thesis based on this filing alone.

Insider Trade Summary

Net Seller: 18,160 shares ($103,695)

Net Sell 1 txn

Insider Silverstein Christine Berni

Role null

Sold 18,160 shs ($104K)

Type	Security	Shares	Price	Value
Sale	Common Stock	18,160	$5.7101	$104K

Holdings After Transaction: Common Stock — 119,562 shares (Direct, null)

Footnotes (1)

The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.68 to $5.73 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Key Figures

Shares sold: 18,160 shares Weighted average sale price: $5.7101 per share Price range of sales: $5.68–$5.73 per share +2 more

5 metrics

Shares sold 18,160 shares Open-market sale on 2026-06-15 to cover tax obligations

Weighted average sale price <money>$5.7101</money> per share Common stock sale in multiple transactions between $5.68 and $5.73

Price range of sales <money>$5.68</money>–<money>$5.73</money> per share Range of individual trade prices included in the reported sale

Shares held after transaction 119,562 shares Director’s direct ownership following the reported sale

Net shares sold 18,160 shares Net-sell direction from transaction summary

Key Terms

restricted stock awards, weighted average price, open-market sale, Form 4

4 terms

restricted stock awards financial

"to cover tax obligations associated with the vesting of restricted stock awards"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The sale reported in this Form 4 was to cover tax obligations"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/15/2026 - 07:49 PM Accepted by SEC EDGAR 06/15/2026 - 07:48 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Silverstein Christine Berni

(Last)

(First)

(Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND

OHIO

44103

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/15/2026		S⁽¹⁾		18,160	D	$5.7101⁽²⁾	119,562	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.68 to $5.73 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Christine Silverstein	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Abeona Therapeutics (ABEO) report in this Form 4?

Abeona Therapeutics reported that director Christine Berni Silverstein sold 18,160 shares of common stock. The shares were sold in open-market transactions at a weighted average price of $5.7101 per share, according to the Form 4 disclosure and accompanying footnotes.

Why did Christine Berni Silverstein sell Abeona Therapeutics (ABEO) shares?

The Form 4 footnotes state the sale was made to cover tax obligations from vesting restricted stock awards. This indicates the transaction is primarily a compensation-related tax event, rather than a discretionary decision to reduce overall exposure to Abeona Therapeutics stock.

How many Abeona Therapeutics (ABEO) shares does the director hold after the sale?

After selling 18,160 shares, Christine Berni Silverstein directly holds 119,562 shares of Abeona Therapeutics common stock. This post-transaction holding, disclosed in the Form 4, shows she continues to maintain a meaningful ownership stake in the company’s equity.

What price range were Abeona Therapeutics (ABEO) shares sold at in this transaction?

The Form 4 notes that shares were sold in multiple transactions at prices between $5.68 and $5.73 per share. The reported price of $5.7101 is a weighted average, and the filing offers to provide full breakdowns upon request to interested parties.

Is the Abeona Therapeutics (ABEO) insider sale considered open-market?

Yes. The transaction is coded as an open-market sale of common stock, with a weighted average sale price of $5.7101 per share. However, a key footnote clarifies that the primary purpose was to cover tax obligations from the vesting of restricted stock awards.